Barclays initiated coverage of Teladoc (TDOC) with an Equal Weight rating and $8.50 price target The firm started the U.S healthcare technology and distribution industry with a neutral view. Barclays is most bullish on the drug distributors and has a more mixed view of the dental and healthcare information technology sub-sectors.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TDOC:
- Private Markets: Prediction market platform Kalshi secures $300M
- Teladoc price target lowered to $8 from $9 at BofA
- Teladoc’s Mixed User Growth and Cautious Outlook Lead to Hold Rating
- Teladoc initiated with a Market Perform at BMO Capital
- Teladoc’s Growth and Execution Challenges: A ‘Show-Me’ Story with Potential Market Opportunities